Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1

Status

Completed 8Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Dermatologic 8CNS 2

Conditions

Carcinoma, Basal Cell 8Medulloblastoma 5Recurrence 4Thrombocythemia, Essential 2Skin Neoplasms 2Primary Myelofibrosis 2Polycythemia Vera 2Ovarian Neoplasms 2Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Astrocytoma 2Thrombocytosis 1Stomach Neoplasms 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms, Basal Cell 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1

Interventions

HhAntag691 18Imiquimod 10sonidegib 8Photochemotherapy 71-phenyl-3,3-dimethyltriazene 6methyl 5-aminolevulinate 4Surgical Procedures, Operative 4Biopsy 4Aminolevulinic Acid 4cemiplimab 3Mohs Surgery 3Microscopy, Confocal 3Itraconazole 3IPI-926 33-ingenyl angelate 3tazarotene 2Microarray Analysis 2Laser Therapy 2Gene Expression Profiling 2Eflornithine 2Drug Evaluation 2Acitretin 2tozuleristide 1teriflunomide 1talimogene laherparepvec 1silmitasertib 1remetinostat 1pembrolizumab 1gusacitinib 1green tea extract polyphenone E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Completed × Carcinoma, Basal Cell × sonidegib × Clear all
NCT04066504 2026-03-18

NISSO

Sun Pharmaceutical Industries Limited

Completed
323 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT03534947 2025-12-16

SONIB

Melanoma Institute Australia

Phase 2 Completed
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT07068568 2025-07-16

BCC-Sonidegib

Federico II University

Completed
12 enrolled
Dermatologic

Carcinoma, Basal Cell, Eyelid Neoplasms, Neoplasms, Basal Cell

NCT00880308 2020-12-19

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
103 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01208831 2020-12-19

An East Asian Study of LDE225

Novartis

Phase 1 Completed
45 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01327053 2019-08-28

BOLT

Novartis

Phase 2 Completed
230 enrolled 26 charts
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT01529450 2017-01-16

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Stanford University

Phase NA Completed
11 enrolled 10 charts
Dermatologic

Carcinoma, Basal Cell

NCT01350115 2015-10-19

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Novartis

Phase 2 Completed
10 enrolled 9 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡